Track topics on Twitter Track topics that are important to you
Verseon has started dosing in a Phase I clinical trial evaluating VE-1902 for the prevention of stroke and heart attack...Read More... The post Verseon starts dosing in trial of VE-1902 to treat CAD a...
The early-stage trial will study safety, pharmacokinetics, and pharmacodynamics of VE-1902 in 100-120 participants. The blood thinner is the first PRrecision Oral AntiCoagulant (PROAC) of the US-based...
Verseon is launching a security token offering (STO) aiming to set a new standard for the 21st century public offering to a globally connected investor base. To make its ST...
BlockRules, the blockchain fintech company enforcing complex compliance rules directly on the blockchain, today announces that the first security token powered by its technology w...
One in three long-term diabetes patients will develop diabetic macular edema (DME), which can lead to blindness. Present DME treatments are recurring inj...
Technology-based pharma company Verseon presented two lead candidates from its new class of precision oral anticoagulants (PROACs) at last week’s International Stroke Con...
Oral drugs could provide a much-needed alternative to current eye injections One third of long-term diabetic patients are at risk of developing diabetic...
Verseon is a technology-based pharmaceutical company that employs its proprietary computational drug discovery platform to develop novel therapeutics for todayâs challenging ...
Verseon Corporation (www.verseon.com, AIM: VSN) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, ...
We have published hundreds of Verseon news stories on BioPortfolio along with dozens of Verseon Clinical Trials and PubMed Articles about Verseon for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Verseon Companies in our database. You can also find out about relevant Verseon Drugs and Medications on this site too.